GCCL and Humic Sign Strategic Business Agreement... "Strengthening Technical Cooperation"

GCCL, a clinical trial specimen analysis institution, announced on the 28th that it has signed a strategic business agreement (MOU) with Humic, a non-clinical contract research organization (CRO) specializing in humanized mouse technology in Korea.

GCCL, a clinical trial specimen analysis institution, announced on the 28th that it has signed a strategic business agreement (MOU) with Humic, a non-clinical contract research organization (CRO) specializing in humanized mouse technology in Korea. Songhyun Yang, CEO of GCCL (left), and Jooyoung Seo, advisor of Humic, are taking a commemorative photo at the signing ceremony.
[Photo by GCCL]

The agreement includes ▲ joint research and technical support ▲ inspection consignment and subcontracting, academic activities, and technology transfer of analytical methods ▲ promotion of external cooperative projects and joint marketing. In particular, both companies plan to strengthen technological cooperation to increase the success rate from non-clinical to clinical trial applications and reduce delays, thereby providing better analytical services to new drug development companies.

Humic is a non-clinical CRO that provides efficacy services in an environment similar to the human immune system using specialized humanized mouse technology. It offers PADO (Patient Derived Organoid) services analyzing animal models based on the biological similarity of organoids in various fields such as cancer, autoimmune diseases, and brain disorders, as well as multi-omics analysis services and single-cell gene analysis services.

GCCL is a clinical trial specimen analysis specialist certified by the Ministry of Food and Drug Safety with GCLP (Good Clinical Laboratory Practice) accreditation, providing full-cycle analysis services from clinical phase 1 to phase 4. The company expects that through this agreement, it will be possible to offer a broader range of services from non-clinical to the entire clinical cycle by leveraging research analysis and partnership technologies.

Yang Songhyun, CEO of GCCL, said, "Through this agreement, we can provide expanded specimen analysis services to new drug development companies based on enhanced technological capabilities from non-clinical to the entire clinical cycle. By combining GCCL's clinical trial analysis expertise with Humic's specialized analytical platform, both companies will jointly offer differentiated analytical services."

This content was produced with the assistance of AI translation services.